Journal article
Long-Term Outcomes of Elagolix in Women With Endometriosis
Abstract
OBJECTIVE: To evaluate the efficacy and safety of elagolix, an oral, nonpeptide gonadotropin-releasing hormone antagonist, over 12 months in women with endometriosis-associated pain.
METHODS: Elaris Endometriosis (EM)-III and -IV were extension studies that evaluated an additional 6 months of treatment after two 6-month, double-blind, placebo-controlled phase 3 trials (12 continuous treatment months) with two elagolix doses (150 mg once daily …
Authors
Surrey E; Taylor HS; Giudice L; Lessey BA; Abrao MS; Archer DF; Diamond MP; Johnson NP; Watts NB; Gallagher JC
Journal
Obstetrics and Gynecology, Vol. 132, No. 1, pp. 147–160
Publisher
Wolters Kluwer
Publication Date
July 2018
DOI
10.1097/aog.0000000000002675
ISSN
0029-7844